1
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Thoracic Malignancies
- Tumour Sub-type
- Non-small-cell Lung Cancer
- Tumour Sub-Group
- EGFR+
- Tumour stage
- Metastatic
- Control Arm
- Placebo
- Treatment Setting
- Stage III or IV disease maintenance after responding to 4-6 cycles platinum doublet
- Trial Name
- SATURN
Primary Outcome(s)
- Primary Outcome(s)
- PFS
- Evaluated Outcome
- OS
- Form(s)
- Form 2a
Outcome Data
- PFS Control
- 11.1 weeks
- PFS Gain
- 1.2 weeks
- PFS HR
- 0.71 (0.62-0.82)
- OS Control
- 11 months
- OS Gain
- 1 month
- OS HR
- 0.81 (0.70-0.95)
Final Score (after adjustments)
- Preliminary non-curative score
- 1
- Final non-curative Score
- 1
- Last update
- 26.10.2020
DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; FFS, failure-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; MFS, metastasis-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PE, point estimate; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate; SD, stable disease; SSA, somatostatin analogue; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor, TTP, time to progression